DoxorubicinAntibiotics, AntineoplasticInduction ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsTaxoidsAntineoplastic AgentsCisplatinCombined Modality TherapyCell Line, TumorDrug Resistance, NeoplasmChemotherapy, AdjuvantRemission InductionTreatment OutcomePaclitaxelApoptosisBreast NeoplasmsCaspase 12Disease-Free SurvivalCyclophosphamideTumor Suppressor Protein p53Survival AnalysisDrug Administration ScheduleNeoadjuvant TherapyNeoplasm StagingSurvival RateEtoposideLung NeoplasmsHead and Neck NeoplasmsFluorouracilAntineoplastic Agents, PhytogenicVincristineCarcinoma, Squamous CellCardiomyopathiesDaunorubicinCytarabineCarboplatinMitochondria, HeartPrognosisVinblastineIfosfamideDNA DamageCarcinoma, Non-Small-Cell LungLeukemia, Myeloid, AcuteDeoxycytidineNeoplasm MetastasisTumor Markers, BiologicalMyocardiumDose-Response Relationship, DrugHeartRNA, MessengerNeoplasm Recurrence, LocalRNA, Small InterferingSignal TransductionGene Expression Regulation, NeoplasticTime FactorsNeutropeniaMethotrexateRadiotherapy, AdjuvantAdenocarcinomaBleomycinEnzyme InductionFollow-Up StudiesChemoradiotherapyTumor BurdenPrecursor Cell Lymphoblastic Leukemia-LymphomaKaplan-Meier EstimateMitoxantroneRadiotherapyInfusions, IntravenousNeoplasmsGranulocyte Colony-Stimulating FactorRadiotherapy DosageIdarubicinSalvage TherapyBone NeoplasmsHypopharyngeal NeoplasmsAnthracyclinesProspective StudiesTumor Necrosis Factor-alphaLaryngectomyAntimetabolites, AntineoplasticDisease ProgressionLeukopeniaTransplantation, AutologousLeukemia, MyeloidP-GlycoproteinNasopharyngeal NeoplasmsPrednisoneBrain NeoplasmsEpirubicinTesticular NeoplasmsOvarian NeoplasmsMelphalanAntibodies, MonoclonalBridged CompoundsLymphatic MetastasisMaximum Tolerated DoseOrganoplatinum CompoundsXenograft Model Antitumor AssaysAntibodies, Monoclonal, Humanized